What Is Referral to Randomization in Clinical Research?

The Six Stages of the Referral-to-Randomization Pathway

Each stage in the pathway has a distinct operational purpose, distinct resource requirements, and distinct dropout risks. Understanding each stage individually is the prerequisite for managing conversion losses across the full pathway.

• Referral receipt and intake: The pathway begins when a referral or inquiry reaches the site and enters the intake process. Intake captures permitted contact details, candidate-reported information, source attribution, and operational status, then routes the record according to the site-approved workflow. Intake quality affects the completeness of information available at later stages.
• Prescreening: Preliminary prescreening collects and organizes candidate-reported information through site-approved questions before authorized site review. Missing, unclear, or apparently mismatched items are documented and escalated rather than interpreted as eligibility decisions. The structured record accompanies the candidate to site handoff, and the site determines eligibility through formal screening.
• Site handoff: The site handoff delivers a structured record to authorized site personnel, including candidate-reported preliminary responses, contact and follow-up history, scheduling context where permitted, unresolved items, escalation notes, and current operational status. The site decides the appropriate clinical and protocol next step.
• Formal screening: Formal screening is controlled by the research site and may include protocol-defined procedures, clinical assessments, and eligibility evaluation. Preliminary prescreening does not replace these activities or determine which criteria a candidate ultimately meets.
• Informed consent: Informed consent is the site-managed process through which the investigator explains the study, answers questions, and obtains documented agreement to participate. Candidates who arrive with accurate expectations about study requirements, established during prescreening, have higher consent completion rates.
• Randomization: Randomization is the formal endpoint of the enrollment pathway: the point at which the candidate is assigned to a study arm and becomes an enrolled participant. The referral-to-randomization conversion rate measures how many referred candidates reach this endpoint, and is the primary metric of enrollment pathway efficiency.

Understanding Referral-to-Randomization Conversion Rate

The referral-to-randomization conversion rate is the proportion of total referred candidates who ultimately randomize. It is the single most comprehensive measure of enrollment pathway efficiency because it captures losses at every stage, including pre-screening dropout that never appears in screen failure statistics.

The limitation of the summary conversion rate is that it does not reveal where losses are occurring. A site converting 8% of referrals to randomization could be losing candidates primarily at the intake-to-prescreening transition, at the prescreening-to-screening transition, or at formal screening. Each pattern has a different operational cause and correction. Stage-specific conversion tracking is the diagnostic tool that makes the summary metric actionable.

For a detailed analysis of where candidates are most commonly lost, see how patients get lost between referral and randomization. For the common structural bottlenecks that produce these losses, see common referral-to-randomization bottlenecks.

The Referral-to-Randomization Pathway as an Operations Problem

The most consequential insight in enrollment operations is the distinction between a candidate supply problem and a conversion problem. Sites that receive adequate referral volume but convert poorly are experiencing an operations failure, not a pipeline failure. The candidates are entering the pathway. The pathway is not moving them through efficiently.

Increasing referral volume in a poorly converting pipeline produces more candidates who get lost at the same failure points. Improving the pipeline produces more enrollments from the existing referral volume. Enrollment operations management works on the pipeline, not just the volume.

The two stages with the greatest opportunity for conversion improvement through structural operations changes are intake and prescreening. Structured clinical trial intake and clinical trial prescreening are the primary mechanisms for addressing conversion losses at these stages. This also directly protects coordinator capacity for clinical responsibilities. For the enrollment infrastructure framework that makes these improvements sustainable across study cycles, see enrollment infrastructure.

How Sponsors Evaluate Referral-to-Randomization Performance

Sponsors and CROs evaluate referral-to-randomization performance as a key indicator of site operational capability. Sites that can provide stage-specific enrollment KPI data, including conversion rates by stage, screen failure attribution, and time-to-randomization trends, demonstrate the operational maturity that sponsors use to make resource allocation and future trial selection decisions.

For a structured approach to building the referral pathway workflow that supports this level of reporting, see referral-to-randomization workflow. For guidance on measuring referral source performance specifically, see referral source performance tracking. To calculate how your current conversion rates affect enrollment timelines, use the Referral to Randomization Calculator. For the operational profile of sites that consistently convert referrals efficiently, see how high-performing research sites manage enrollment operations.